Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)

v3.24.1.u1
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Operating expenses:    
Research and development $ 3,676 $ 3,618
General and administrative 2,065 1,903
Total operating expenses (5,741) (5,521)
Other income, net 597 256
Loss before income tax expense (5,144) (5,265)
Income tax expense (7) (7)
Net loss (5,151) (5,272)
Other comprehensive (loss) gain    
Unrealized gain (loss) on marketable securities (45) 45
Net loss and comprehensive loss $ (5,196) $ (5,227)
Basic and diluted net loss per share (in dollars per share) $ (0.14) $ (0.2)
Weighted average shares outstanding – basic and diluted (in shares) 37,958,000 26,448,941